BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial

Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, Sam R Miller, Duncan Richards, James Storey, George Dukes, Kim Gilchrist, Susan Vallow, Graeme J Alexander, Margaret Corrigan, Gideon M Hirschfield, David E J Jones, Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, Sam R Miller, Duncan Richards, James Storey, George Dukes, Kim Gilchrist, Susan Vallow, Graeme J Alexander, Margaret Corrigan, Gideon M Hirschfield, David E J Jones

Abstract

Background: Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels in the systemic circulation and improve pruritus.

Methods: This clinical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studies supported by the National Institute for Health Research (NIHR). It is a phase 2a, multi-centre, randomised, double bind, placebo controlled, cross-over trial for PBC patients with pruritus. The primary objective is to investigate the safety and tolerability of repeat doses of GSK2330672, and explore whether GSK2330672 administration for 14 days improves pruritus compared with placebo. The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale and other PBC symptoms in an electronic diary completed twice daily by the patients. The secondary outcomes include the evaluation of the effect of GSK2330672 on total serum bile acid (BA) concentrations, serum markers of BA synthesis and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).

Discussion: BAT117213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor, a novel class of drug to treat pruritus in PBC. The main strengths of the trial are utility of a novel, study specific, electronic symptom diary as patient reported outcome to measure the treatment response objectively and the crossover design that allows estimating the treatment effect in a smaller number of patients. The outcome of this trial will inform the trial design of future development phase of the IBAT inhibitor drug. The trial will also provide opportunity to conduct metabonomic and gut microbiome studies as explorative and mechanistic research in patients with cholestatic pruritus.

Trial registration: EudraCT number: 2012-005531-84, ClinicalTrials.gov Identifier: NCT01899703 , registered on 3(rd) July 2013.

Keywords: IBAT; Ileal bile acid transporter; PBC; Primary biliary cholangitis; Pruritus.

Figures

Fig. 1
Fig. 1
Mechanism of IBAT (ASBT) inhibitor drug. GSK2330672 interrupts the enterohepatic circulation of bile acids by selectively inhibiting the IBAT protein located in the terminal ileum, thereby reducing the levels of bile acids in the systemic circulation. (Image reproduced with permission from [31]). IBAT, ileal bile acid transporter; ASBT, apical sodium-dependent bile acid transporter
Fig. 2
Fig. 2
Flowchart of BAT117213 study design

References

    1. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):318–28. doi: 10.1055/s-0034-1383730.
    1. Beuers U, Boberg KM, Chapman RW, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67. doi: 10.1016/j.jhep.2009.04.009.
    1. Hegade VS, Mells GF, Beuers U, et al. Patient Experience and Characteristics of Cholestatic Pruritus in the UK-PBC Research Cohort. Hepatology. 2014;60:339A–69. doi: 10.1002/hep.27496.
    1. Hegade VS, Mells GF, Lammert C, et al. A Comparative Study of Pruritus in PBC cohorts from UK, USA and Italy. J Hepatol. 2015;62:S785. doi: 10.1016/S0168-8278(15)31349-0.
    1. Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273–83. doi: 10.1002/hep.26365.
    1. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308. doi: 10.1002/hep.22906.
    1. Dyson JK, Webb G, Hirschfield GM, et al. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62(1):208–18. doi: 10.1016/j.jhep.2014.09.010.
    1. Dawson PA, Haywood J, Craddock AL, et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem. 2003;278(36):33920–7. doi: 10.1074/jbc.M306370200.
    1. Lanzini A, De Tavonatti MG, Panarotto B, et al. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut. 2003;52(9):1371–5. doi: 10.1136/gut.52.9.1371.
    1. Hegade VS, Krawczyk M, Kremer AE, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016;43(2):294–302. doi: 10.1111/apt.13449.
    1. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13(11):1393–4. doi: 10.1097/00042737-200111000-00022.
    1. Wong MH, Oelkers P, Dawson PA. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J Biol Chem. 1995;270(45):27228–34. doi: 10.1074/jbc.270.45.27228.
    1. Baghdasaryan A, Fuchs CD, Osterreicher CH, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64(3):674–81. doi: 10.1016/j.jhep.2015.10.024.
    1. Graffner H, Gillberg PG, Rikner L, Marschall HU. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303–10. doi: 10.1111/apt.13457.
    1. Jopson L, Newton JL, Palmer J, et al. RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMJ Open. 2015;5(8):e007985. doi: 10.1136/bmjopen-2015-007985.
    1. Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622–9. doi: 10.1136/gut.2005.065862.
    1. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587–93. doi: 10.1111/j.1365-2133.2009.09586.x.
    1. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26(8):943–8. doi: 10.1111/j.1478-3231.2006.01326.x.
    1. Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102(7):1528–36. doi: 10.1111/j.1572-0241.2007.01200.x.
    1. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50(3):323–32.
    1. Oster ZH, Rachmilewitz EA, Moran E, Stein Y. Relief of pruritus by cholestyramine in chronic liver disease. Isr J Med Sci. 1965;1(4):599–606.
    1. Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J. 1963;1(5325):216–9. doi: 10.1136/bmj.1.5325.216.
    1. Van Itallie TB, Hashim SA, Crampton RS, Tennent DM. The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine. N Engl J Med. 1961;265:469–74. doi: 10.1056/NEJM196109072651004.
    1. Carey JB, Jr, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA. 1961;176:432–5. doi: 10.1001/jama.1961.03040180034008.
    1. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37(6):717–22. doi: 10.1016/S0168-8278(02)00318-5.
    1. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–9. doi: 10.1053/gast.1997.v113.pm9322521.
    1. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94(2):488–93. doi: 10.1016/0016-5085(88)90442-8.
    1. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–74. doi: 10.1002/hep.21553.
    1. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006;44(5):1317–23. doi: 10.1002/hep.21370.
    1. Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(4):1334–40. doi: 10.1002/hep.23821.
    1. Hegade VS, Kendrick SF, Jones DE. Drug treatment of pruritus in liver diseases. Clin Med. 2015;15(4):351–7.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera